

Human IL-20RA Protein

Cat. No. IL2-HM2RA

Description

Source	Recombinant Human IL-20RA Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Val30-Lys250.
Accession	Q9UHF4-1
Molecular Weight	The protein has a predicted MW of 52 kDa. Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 $\mu\text{g}/\text{ml}$ is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

IL-20RA was highly expressed in the tumor tissue of CRC and related to the advanced stage. IL-20RA was involved in regulating oncogenic and immune pathways and affecting the expression of genes related to cell proliferation and immune evasion in CRC. Super-enhancer inhibition by JQ-1 or iBET-151 suppressed the growth of tumor cells and inhibited the expression of IL-20RA.


Assay Data

Bis-Tris PAGE



Human IL-20RA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human IL-20RA is greater than 95% as determined by SEC-HPLC.